Radical cystectomy is the standard treatment for patients with bladder cancer, but the prognosis of patients undergoing this procedure has not changed for decades. Small steps towards improvement include better selection of high-risk T1 patients, the use of perioperative chemotherapy and, maybe, robotic cystectomy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Melatonin and urological cancers: a new therapeutic approach
Cancer Cell International Open Access 10 September 2020
-
UBIAD1 suppresses the proliferation of bladder carcinoma cells by regulating H-Ras intracellular trafficking via interaction with the C-terminal domain of H-Ras
Cell Death & Disease Open Access 05 December 2018
-
Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer
Cell Death & Disease Open Access 15 February 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
van den Bosch, S. & Witjes, J. A. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur. Urol. 60, 493–500 (2011).
Martin-Doyle, W., Leow, J. J., Orsola, A., Chang, S. L. & Bellmunt, J. Improving selection criteria for early cystectomy in high-grade T1 bladder cancer: a meta-analysis of 15,215 patients. J. Clin. Oncol. 33, 643–650 (2015).
Novara, G. et al. Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy. Eur. Urol. 67, 376–401 (2015).
Bochner, B. H. et al. Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial. Eur. Urol. 67, 1042–1050 (2015).
Wilson, T. G. et al. Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel. Eur. Urol. 67, 363–375 (2015).
Sternberg, C. N. et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 16, 76–86 (2015).
Zargar, H. et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur. Urol. 67, 241–249 (2015).
Svatek, R. S. et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin. Cancer Res. 16, 4461–4467 (2010).
Leow, J. J. et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur. Urol. 66, 42–54 (2014).
Reardon, Z. D. et al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur. Urol. 67, 165–170 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Witjes, J. Improving indication, technique and outcome of radical cystectomy. Nat Rev Urol 13, 74–76 (2016). https://doi.org/10.1038/nrurol.2015.272
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2015.272
This article is cited by
-
Melatonin and urological cancers: a new therapeutic approach
Cancer Cell International (2020)
-
Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer
Cell Death & Disease (2018)
-
UBIAD1 suppresses the proliferation of bladder carcinoma cells by regulating H-Ras intracellular trafficking via interaction with the C-terminal domain of H-Ras
Cell Death & Disease (2018)